LIMN · Liminatus Pharma Inc
United States · RS rating 90 · As of 2026-11-03
| Price | 2.79 USD |
|---|---|
| 1-day change | +10.7% |
| RS rating (overall / 1M / 3M / 12M) | 90 / 12 / 99 / 94 |
| Stage | Advancing |
| Composite / Minervini / CANSLIM score | 29 / 59 / 35 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | – |
| Distance from 52-week high | +45.9% |
| Market cap (USD) | $9.0M |